(EXEL) Exelixis, Inc. Business Model Canvas Research

In 2025, Exelixis used Catalent Pharma Solutions, R.P. Scherer, and Redwood Bioscience for formulation, delivery, and biotech services, so it can keep drug-development work external instead of building every capability in-house. That reduces fixed capex and speeds scale-up across its pipeline.

• Externalize formulation and delivery
• Use specialist biotech services
• Lower internal build-out costs
• Speed development and manufacturing

NBE, Aurigene, Invenra, and StemSynergy sit in Exelixis, Inc.'s broader research-partnership web, helping source oncology discovery tools and new candidates. That network matters: Exelixis reported $2.17B in total revenue in FY2024, and its partnered R&D model supports pipeline growth beyond cabozantinib.

• External discovery access
• Oncology pipeline expansion
• New-target and platform options

Exelixis, Inc. runs a broad licensing and alliance network, so deal management is core to how it shares development risk, keeps regional rights clear, and lets partners handle commercialization. In 2025, this model helped support multi-product revenue above $2 billion while its alliance base continued to fund pipeline work.

• Shared development cuts cash burn.
• Regional rights expand reach.
• Partners drive local sales.

Exelixis keeps marketed drugs compliant by managing FDA approvals, safety monitoring, and label changes, which helps protect its approved revenue base. In FY2024, the Company generated more than $2.1 billion in total revenue, showing how lifecycle work on CABOMETYX and other therapies directly supports cash flow.

• Maintain product approvals and safety
• Update labels and indications
• Extend revenue from approved therapies

Exelixis, Inc. uses a broad licensing and partnership network with pharma, biotech, and tech peers, so it can expand drug discovery, development, and commercialization without owning every asset. A clear example is the cabozantinib alliance with Ipsen, which supports ex-U.S. reach while Exelixis keeps a leaner core.

• Shares risk and R&D cost
• Extends market access faster
• Supports royalty and milestone income

This network is a key resource because it turns external science and distribution into scale; as of FY2025, Exelixis still relies on partnerships to widen its pipeline while focusing internal capital on its highest-value programs.

Exelixis is based in Alameda, California, and its main resource is the 2025 biotech team that drives research, development, and commercialization. In fiscal 2025, the company generated about $2.3 billion in net product revenue and spent about $1.0 billion on R&D, showing how tightly human capital and scientific know-how sit at the core of the model.

That Alameda base supports work on discovery, clinical trials, and market launch, so the site is not just an office but the operating hub for the business. The resource mix is simple: skilled people, lab expertise, and a cash-backed R&D engine.

• Alameda HQ anchors execution
• 2025 revenue: about $2.3 billion
• 2025 R&D: about $1.0 billion
• Scientiic talent is the key asset

MINNEBRO gives Exelixis a Japan-only, non-oncology revenue stream: it is an oral, non-steroidal selective mineralocorticoid receptor blocker approved for hypertension, a market affecting about 43 million adults in Japan. With chronic use in a large, aging population, it adds durable commercial value beyond oncology.

• Oral, once-daily hypertension therapy
• Non-steroidal selective MRA
• Approved in Japan
• Non-oncology sales stream

Exelixis, Inc.’s oral targeted pipeline adds 3 assets—XL092, XB002, and XL102—built to hit VEGF, MET, AXL, TF, and CDK7 biology in cancer. That broadens the company’s future treatment mix beyond a single lead drug and supports more shots at durable, biomarker-driven value.

• 3 oral pipeline assets
• 5 cancer pathways targeted
• More future treatment options

Exelixis, Inc. uses alliance partners in selected markets, so local teams handle relationships, pricing, and execution while Exelixis keeps a lighter direct footprint. That model helps the company scale cabozantinib and other oncology assets without building a full sales force in every region; in 2024, collaboration revenue still supported a top line above $2 billion.

• Partner-led local market execution
• Lower direct operating burden
• Supports international scale

Exelixis, Inc. must keep post-market safety watch on approved therapies like Cabometyx, so it can detect, assess, and report adverse events to regulators and clinicians. This is a continuous duty, and FDA pharmacovigilance rules require ongoing safety reporting after approval.

In 2025, this relationship stayed active across real-world use, with safety data shaping label updates and risk review.

• Ongoing adverse-event monitoring
• Mandatory safety reporting
• Regulator and clinician contact

Exelixis uses Takeda and Ipsen to push cabozantinib in non-U.S. licensed markets, giving it local sales reach, pricing access, and regulatory support without building those teams itself. In 2025, Exelixis reported about $2.2 billion in total revenue, and partner-run markets remain a key non-U.S. growth lane.

• Takeda and Ipsen drive local execution
• Supports access outside the U.S.
• Reduces Exelixis' direct market cost

Exelixis uses scientific and medical communication to move clinical evidence through data presentations, peer-reviewed publications, and field education, so physicians can judge therapy value from clear trial results. This channel helps build trust in the Company Name’s medicines by turning study data into practical, treatment-level evidence.

• Congress data supports physician awareness
• Publications validate trial outcomes
• Education builds confidence in use

MINNEBRO targets adults treated for hypertension in Japan, so Exelixis, Inc. gets revenue outside oncology and lowers dependence on cancer sales. The Japanese hypertension market is large and chronic, which supports repeat use and gives Exelixis, Inc. geographic and therapeutic diversification.

• Adult hypertension patients in Japan
• Non-oncology revenue stream
• Diversifies country and therapy mix

For Exelixis, Inc., this segment matters because it adds a steady, local prescription base beyond its U.S. cancer portfolio.

Oncologists, hospitals, and payers drive Exelixis' access to cabozantinib and zanzalintinib; they decide prescribing, formulary placement, and reimbursement. In 2024, Exelixis reported $2.17B in total revenue, so even small shifts in hospital protocols or payer rules can move sales fast.

• Oncologists drive first-line use
• Hospitals set treatment pathways
• Payers control coverage and price

Sales and marketing is a major commercial cost for Exelixis, Inc. because oncology products need field teams, medical education, congress presence, and payer access support to keep awareness and reimbursement strong. This spend scales with product launches and label expansion, so it stays a key driver of SG&A pressure.

• Field teams drive prescriber reach.
• Medical comms support access and uptake.

Exelixis, Inc. still carries recurring royalty and alliance-fee costs because its licensing model depends on external partners, milestone payments, and shared economics. In FY2025, with revenue above $2 billion, these deal-linked obligations stayed a real margin drag, so every new collaboration can add both cash outflow and profit sharing.

• Milestone payments hit cash flow
• Royalties cut partner economics
• Alliance fees recur with deals

MINNEBRO adds a Japan hypertension royalty stream to Exelixis, and the Takeda-linked commercialization helps support this non-oncology revenue. Exelixis does not disclose MINNEBRO sales separately in FY2025 filings, so the cash flow is folded into collaboration revenue rather than reported as a stand-alone line.

• Japan hypertension royalties
• Takeda commercialization support
• Diversifies beyond oncology

Exelixis earns revenue from collaborations and licenses through upfront fees, development milestones, and sales-based royalties. This matters because its partner network spans multiple programs, so one deal can create income at several stages, not just at signing.

• Upfront cash at deal start

• Milestone payments as targets are hit

• Royalties on partner sales